A kinome-wide RNAi screen identifies ERK2 as a druggable regulator of Shank3 stability

Li Wang, Carolyn J. Adamski, Vitaliy V. Bondar, Evelyn Craigen, John R. Collette, Kaifang Pang, Kihoon Han, Antrix Jain, Sung Y. Jung, Zhandong Liu, Richard N. Sifers, J. Lloyd Holder, Huda Y. Zoghbi

Research output: Contribution to journalArticle

Abstract

Neurons are sensitive to changes in the dosage of many genes, especially those regulating synaptic functions. Haploinsufficiency of SHANK3 causes Phelan-McDermid syndrome and autism, whereas duplication of the same gene leads to SHANK3 duplication syndrome, a disorder characterized by neuropsychiatric phenotypes including hyperactivity and bipolar disorder as well as epilepsy. We recently demonstrated the functional modularity of Shank3, which suggests that normalizing levels of Shank3 itself might be more fruitful than correcting pathways that function downstream of it for treatment of disorders caused by alterations in SHANK3 dosage. To identify upstream regulators of Shank3 abundance, we performed a kinome-wide siRNA screen and identified multiple kinases that potentially regulate Shank3 protein stability. Interestingly, we discovered that several kinases in the MEK/ERK2 pathway destabilize Shank3 and that genetic deletion and pharmacological inhibition of ERK2 increases Shank3 abundance in vivo. Mechanistically, we show that ERK2 binds Shank3 and phosphorylates it at three residues to promote its poly-ubiquitination-dependent degradation. Altogether, our findings uncover a druggable pathway as a potential therapeutic target for disorders with reduced SHANK3 dosage, provide a rich resource for studying Shank3 regulation, and demonstrate the feasibility of this approach for identifying regulators of dosage-sensitive genes.

Original languageEnglish
JournalMolecular Psychiatry
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Gene Dosage
RNA Interference
MAP Kinase Kinase Kinases
Haploinsufficiency
Gene Duplication
Protein Stability
Ubiquitination
Autistic Disorder
Bipolar Disorder
Small Interfering RNA
Epilepsy
Phosphotransferases
Pharmacology
Phenotype
Neurons
Therapeutics
Telomeric 22q13 Monosomy Syndrome
Inhibition (Psychology)

ASJC Scopus subject areas

  • Molecular Biology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience

Cite this

Wang, L., Adamski, C. J., Bondar, V. V., Craigen, E., Collette, J. R., Pang, K., ... Zoghbi, H. Y. (2019). A kinome-wide RNAi screen identifies ERK2 as a druggable regulator of Shank3 stability. Molecular Psychiatry. https://doi.org/10.1038/s41380-018-0325-9

A kinome-wide RNAi screen identifies ERK2 as a druggable regulator of Shank3 stability. / Wang, Li; Adamski, Carolyn J.; Bondar, Vitaliy V.; Craigen, Evelyn; Collette, John R.; Pang, Kaifang; Han, Kihoon; Jain, Antrix; Y. Jung, Sung; Liu, Zhandong; Sifers, Richard N.; Holder, J. Lloyd; Zoghbi, Huda Y.

In: Molecular Psychiatry, 01.01.2019.

Research output: Contribution to journalArticle

Wang, L, Adamski, CJ, Bondar, VV, Craigen, E, Collette, JR, Pang, K, Han, K, Jain, A, Y. Jung, S, Liu, Z, Sifers, RN, Holder, JL & Zoghbi, HY 2019, 'A kinome-wide RNAi screen identifies ERK2 as a druggable regulator of Shank3 stability', Molecular Psychiatry. https://doi.org/10.1038/s41380-018-0325-9
Wang, Li ; Adamski, Carolyn J. ; Bondar, Vitaliy V. ; Craigen, Evelyn ; Collette, John R. ; Pang, Kaifang ; Han, Kihoon ; Jain, Antrix ; Y. Jung, Sung ; Liu, Zhandong ; Sifers, Richard N. ; Holder, J. Lloyd ; Zoghbi, Huda Y. / A kinome-wide RNAi screen identifies ERK2 as a druggable regulator of Shank3 stability. In: Molecular Psychiatry. 2019.
@article{04c154c557db4b25a5ee468624b57359,
title = "A kinome-wide RNAi screen identifies ERK2 as a druggable regulator of Shank3 stability",
abstract = "Neurons are sensitive to changes in the dosage of many genes, especially those regulating synaptic functions. Haploinsufficiency of SHANK3 causes Phelan-McDermid syndrome and autism, whereas duplication of the same gene leads to SHANK3 duplication syndrome, a disorder characterized by neuropsychiatric phenotypes including hyperactivity and bipolar disorder as well as epilepsy. We recently demonstrated the functional modularity of Shank3, which suggests that normalizing levels of Shank3 itself might be more fruitful than correcting pathways that function downstream of it for treatment of disorders caused by alterations in SHANK3 dosage. To identify upstream regulators of Shank3 abundance, we performed a kinome-wide siRNA screen and identified multiple kinases that potentially regulate Shank3 protein stability. Interestingly, we discovered that several kinases in the MEK/ERK2 pathway destabilize Shank3 and that genetic deletion and pharmacological inhibition of ERK2 increases Shank3 abundance in vivo. Mechanistically, we show that ERK2 binds Shank3 and phosphorylates it at three residues to promote its poly-ubiquitination-dependent degradation. Altogether, our findings uncover a druggable pathway as a potential therapeutic target for disorders with reduced SHANK3 dosage, provide a rich resource for studying Shank3 regulation, and demonstrate the feasibility of this approach for identifying regulators of dosage-sensitive genes.",
author = "Li Wang and Adamski, {Carolyn J.} and Bondar, {Vitaliy V.} and Evelyn Craigen and Collette, {John R.} and Kaifang Pang and Kihoon Han and Antrix Jain and {Y. Jung}, Sung and Zhandong Liu and Sifers, {Richard N.} and Holder, {J. Lloyd} and Zoghbi, {Huda Y.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41380-018-0325-9",
language = "English",
journal = "Molecular Psychiatry",
issn = "1359-4184",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - A kinome-wide RNAi screen identifies ERK2 as a druggable regulator of Shank3 stability

AU - Wang, Li

AU - Adamski, Carolyn J.

AU - Bondar, Vitaliy V.

AU - Craigen, Evelyn

AU - Collette, John R.

AU - Pang, Kaifang

AU - Han, Kihoon

AU - Jain, Antrix

AU - Y. Jung, Sung

AU - Liu, Zhandong

AU - Sifers, Richard N.

AU - Holder, J. Lloyd

AU - Zoghbi, Huda Y.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Neurons are sensitive to changes in the dosage of many genes, especially those regulating synaptic functions. Haploinsufficiency of SHANK3 causes Phelan-McDermid syndrome and autism, whereas duplication of the same gene leads to SHANK3 duplication syndrome, a disorder characterized by neuropsychiatric phenotypes including hyperactivity and bipolar disorder as well as epilepsy. We recently demonstrated the functional modularity of Shank3, which suggests that normalizing levels of Shank3 itself might be more fruitful than correcting pathways that function downstream of it for treatment of disorders caused by alterations in SHANK3 dosage. To identify upstream regulators of Shank3 abundance, we performed a kinome-wide siRNA screen and identified multiple kinases that potentially regulate Shank3 protein stability. Interestingly, we discovered that several kinases in the MEK/ERK2 pathway destabilize Shank3 and that genetic deletion and pharmacological inhibition of ERK2 increases Shank3 abundance in vivo. Mechanistically, we show that ERK2 binds Shank3 and phosphorylates it at three residues to promote its poly-ubiquitination-dependent degradation. Altogether, our findings uncover a druggable pathway as a potential therapeutic target for disorders with reduced SHANK3 dosage, provide a rich resource for studying Shank3 regulation, and demonstrate the feasibility of this approach for identifying regulators of dosage-sensitive genes.

AB - Neurons are sensitive to changes in the dosage of many genes, especially those regulating synaptic functions. Haploinsufficiency of SHANK3 causes Phelan-McDermid syndrome and autism, whereas duplication of the same gene leads to SHANK3 duplication syndrome, a disorder characterized by neuropsychiatric phenotypes including hyperactivity and bipolar disorder as well as epilepsy. We recently demonstrated the functional modularity of Shank3, which suggests that normalizing levels of Shank3 itself might be more fruitful than correcting pathways that function downstream of it for treatment of disorders caused by alterations in SHANK3 dosage. To identify upstream regulators of Shank3 abundance, we performed a kinome-wide siRNA screen and identified multiple kinases that potentially regulate Shank3 protein stability. Interestingly, we discovered that several kinases in the MEK/ERK2 pathway destabilize Shank3 and that genetic deletion and pharmacological inhibition of ERK2 increases Shank3 abundance in vivo. Mechanistically, we show that ERK2 binds Shank3 and phosphorylates it at three residues to promote its poly-ubiquitination-dependent degradation. Altogether, our findings uncover a druggable pathway as a potential therapeutic target for disorders with reduced SHANK3 dosage, provide a rich resource for studying Shank3 regulation, and demonstrate the feasibility of this approach for identifying regulators of dosage-sensitive genes.

UR - http://www.scopus.com/inward/record.url?scp=85060798163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060798163&partnerID=8YFLogxK

U2 - 10.1038/s41380-018-0325-9

DO - 10.1038/s41380-018-0325-9

M3 - Article

JO - Molecular Psychiatry

JF - Molecular Psychiatry

SN - 1359-4184

ER -